Correction: Se 2 Mo 10 V 3 , a heteropoly compound containing selenium, inhibits tumor growth

Hong-Ning Zhang; Wei-Li Feng; Chun-Na An; Wen-Guang Li

doi:10.18632/oncotarget.26408

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Se₂Mo₁₀V₃, a heteropoly compound containing selenium, inhibits tumor growth

PDF | How to cite

Oncotarget. 2018; 9:36542-36542. https://doi.org/10.18632/oncotarget.26408

Metrics: PDF 1296 views | ?

Hong-Ning Zhang¹, Wei-Li Feng², Chun-Na An³ and Wen-Guang Li⁴

¹ Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
² Department of Pharmacology, School of Basic Medical Sciences, Qinghai University, Xining 810001, China
³ Department of Pharmacology, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan 063009, China
⁴ Department of Pharmacology, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan 063009, China

Published: November 23, 2018

This article has been corrected: The correct information of the Author contributions and Funding is given below:

Author contributions

H.-N. Z. performed the experiments. W.-L. F. helped to perform the in vitro experiment. C.-N. A. wrote the manuscript, prepared the figures and supplied publication costs. W.-G. L. designed the project. All authors reviewed the manuscript.

FUNDING

This work was supported by Science and Technology Program of Beijing Municipal Education Commission (KM201810025002) and Health Science Key Program of Hebei Province (ZD20140029).

Original article: Oncotarget. 2017; 8:67871-67877. DOI: https://doi.org/10.18632/oncotarget.18909.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26408

Publication Alerts

Corrections:

Correction: Se2Mo10V3, a heteropoly compound containing selenium, inhibits tumor growth

Correction: Se₂Mo₁₀V₃, a heteropoly compound containing selenium, inhibits tumor growth